Drug Profile
Rivaroxaban - Bayer/Johnson & Johnson Pharmaceutical Research & Development
Alternative Names: BAY-59-7939; JNJ-39039039; XareltoLatest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Bayer; Johnson & Johnson Pharmaceutical Research & Development
- Developer Bayer; Janssen Research & Development; Johnson & Johnson; Population Health Research Institute
- Class Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Chlorinated hydrocarbons; Ketones; Morpholines; Oxazolidinones; Small molecules; Thiophenes
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism
- Registered Acute coronary syndromes
- Phase III Arterial thrombosis; Peripheral arterial disorders; Venous thrombosis
- Phase II Coronary thrombosis
- No development reported Heart failure
Most Recent Events
- 16 Apr 2024 Launched for Cardiovascular disorders (Combination therapy, Prevention) in Canada (PO)
- 08 Apr 2024 Updated efficacy data from the phase IIIb PIONEER AF-PCI released by Johnson and Johnson
- 11 Nov 2023 Adverse events and efficacy data from the phase III VOYAGER PAD trial in Peripheral arterial disorders presented at the American Heart Association Scientific Sessions (AHA-2023)